Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mangoceuticals (MGRX) EBITDA Margin (2023 - 2025)

Mangoceuticals (MGRX) has disclosed EBITDA Margin for 3 consecutive years, with 389.72% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 120430.0% to 389.72% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 3954.28% through Dec 2025, down 265986.0% year-over-year, with the annual reading at 3954.28% for FY2025, 265986.0% down from the prior year.
  • EBITDA Margin hit 389.72% in Q4 2025 for Mangoceuticals, up from 8953.45% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 1929.93% in Q4 2023 to a low of 8953.45% in Q3 2025.
  • Historically, EBITDA Margin has averaged 2102.68% across 3 years, with a median of 1461.57% in 2024.
  • Biggest five-year swings in EBITDA Margin: soared 143491bps in 2024 and later tumbled -763524bps in 2025.
  • Year by year, EBITDA Margin stood at 1929.93% in 2023, then crashed by -183bps to 1594.02% in 2024, then skyrocketed by 76bps to 389.72% in 2025.
  • Business Quant data shows EBITDA Margin for MGRX at 389.72% in Q4 2025, 8953.45% in Q3 2025, and 3133.98% in Q2 2025.